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INTRODUCTION
Preterm birth is a major complication of pregnancy, accounting for as many as 28% of all neonatal deaths 1, 2 . Preterm birth occurs in approximately 10% of pregnancies worldwide and is the principal cause of both neonatal mortality and child morbidity 3 . Accurately identifying women at risk of preterm birth would help avoid unnecessary and costly interventions 4 . To improve identification among symptomatic women, methods such as cervical-length (CL) measurement and biochemical testing, including fetal fibronectin (fFN), placental alpha microglobulin-1 (PAMG-1) and cervical phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) have been proposed 5 . Of the available methods, the American College of Obstetricians and Gynecologists advises against the use of either a positive fFN test or a short cervix alone to direct patient management owing to their low positive predictive values (PPV) 6 . Furthermore, the most recent meta-analysis on the efficacy of fFN for the prediction of preterm birth found that there is little reason to justify the routine use of fFN testing 7, 8 . Additionally, the most recent meta-analysis on the efficacy of the phIGFBP-1 test found that there was insufficient evidence to recommend its routine clinical use 4 . According to recently published guidelines of the European Association of Perinatal Medicine on the management of preterm labor, in patients with a CL of between 1.5 and 3.0 cm the use of a biochemical test with the highest combination of negative predictive value (NPV) and PPV that can be run shortly after a vaginal examination is recommended 5 . Based on the recent literature, the guidelines concluded that the most appropriate test is the one using PAMG-1.
In 2013, our institution switched from the fFN to the PAMG-1 as the standard biochemical test for assessing the risk of preterm delivery. The objective of this study was to assess the performance of the PAMG-1 and fFN tests for the prediction of spontaneous preterm delivery in patients presenting to an emergency obstetric unit with symptoms of preterm labor, by conducting a retrospective review of patient records over two different years, in one of which fFN testing was used as the standard of care while in the other the PAMG-1 test was adopted.
PATIENTS AND METHODS
A retrospective cohort study was performed by reviewing the electronic medical records of patients who presented to the emergency obstetric unit of Cruces University Hospital, Vizcaya, Spain, a level-III maternity hospital, during two different years in which either fFN or PAMG-1 was used as the standard-of-care biochemical test to aid in the risk assessment for spontaneous preterm delivery. The study was approved by the hospital's research ethics committee (CEIC E17/22).
The medical records of all patients presenting with threatened preterm labor (regular or irregular contractions, abdominal pressure or pain, dull pulling backache and cramping) between 24 + 0 and 34 + 6 weeks' gestation were reviewed. Patients with a singleton pregnancy at 24 + 0 to 34 + 6 weeks who presented with symptoms of preterm labor, clinically intact membranes and cervical dilatation < 3 cm, and who had a valid biochemical test and digital examination result were included in the analysis. Patients with active vaginal bleeding, placenta previa or cervical cerclage in place at the time of testing were not eligible. Women who had medically indicated preterm delivery within 14 days of testing were excluded from the analysis.
The 'baseline' period was defined as the period from January 2012 to December 2012, during which the qualitative fFN test, with a cut-off of 50 ng/mL (QuikCheck™ fFN test, Hologic, Inc., Sunnyvale, CA, USA), was used as the standard-of-care biochemical test for assessing the risk of preterm delivery. The 'comparative' period was defined as the period from January 2016 to December 2016, during which the PAMG-1 test (PartoSure TM Test, Parsagen Diagnostics Inc., Boston, MA, USA), with a cut-off of 1 ng/mL, was used as the standard-of-care biomarker test.
As this was a retrospective cohort study, the test results were known to the clinicians managing the care of the patients. As depicted in Figure 1 , the diagnosis and management of the patients included an initial assessment of their history and clinical symptoms at the time of presentation, a digital examination, a biochemical test, cardiotocography and transvaginal ultrasound for CL measurement, as appropriate. As CL measurement by transvaginal ultrasound was implemented at our institution as a standard procedure during the baseline period, CL measurements were not available for all patients in this group. The decision to admit/treat was generally considered by the managing physician if the patient had cervical dilatation ≥ 2 cm, CL < 25 mm, a positive biochemical test and/or changes in cervical dilatation and/or effacement upon repeat examination, depending on gestational age at testing. Patients admitted to the hospital and treated for the suspicion of imminent preterm delivery typically received antenatal corticosteroids for fetal lung maturation, magnesium sulfate for neural protection and tocolytics (Atosiban) to allow for administration of the corticosteroids.
Biochemical test samples were collected according to each manufacturer's recommendation and prior to digital examination. fFN samples were collected using a sterile dacron swab that was rotated in the posterior fornix of the vagina for 10 s under speculum examination. The swab was then inserted into the test vial with buffer solution, in which it was thoroughly mixed for 10-15 s. The swab was then replaced by the test strip, which was left to incubate in the buffer for exactly 10 min before being removed and read. PAMG-1 samples were collected using a sterile flocked swab that was inserted 5-7 cm into the vagina for 30 s prior to a speculum examination. The swab was then Figure 1 Diagnostic protocol for preterm labor during year in which fetal fibronectin test (baseline period) and year in which placental alpha microglobulin-1 test (comparative period) were used as standard-of-care biochemical tests for assessment of risk of preterm delivery.
removed and placed in the vial with buffer solution, in which it was actively rotated for 30 s. The swab was then replaced by the test strip and left to incubate for 5 min before it was removed and read. The key parameters used for analysis were biomarker test results, time of testing and time of delivery, as the primary endpoint of this retrospective analysis was spontaneous preterm delivery within 7 and 14 days of testing. Thus, PPV, NPV, sensitivity, specificity and positive and negative likelihood ratios (LR+ and LR-) for the prediction of spontaneous preterm delivery ≤ 7 and ≤ 14 days were calculated for PAMG-1 and fFN.
SAS software (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis, and Fisher's exact test was used to calculate P-values. The Clopper-Pearson procedure was used to calculate 95% CIs for sensitivity and specificity, the standard logit CI procedure given by Mercaldo et al. 9 was used to calculate 95% CIs for PPV and NPV and the Altman 'Log method' was used to calculate 95% CIs for LR+ and LR-.
RESULTS
Four hundred and twenty patients presented with threatened preterm labor during the baseline period, 41 (9.8%) of whom did not meet eligibility criteria and one (0.2%) of whom was excluded for having a medically-indicated preterm delivery within 14 days of testing owing to fetal distress (Figure 2 ). Of the 41 who did not meet the eligibility criteria, 30 had a multiple gestation, eight had cervical dilatation ≥ 3 cm at presentation, one had a gestational age < 24 weeks at presentation, one did not undergo digital examination and one had placenta previa at the time of presentation, which ultimately led to a medically indicated preterm delivery within 14 days of testing. Thus, 378/420 (90.0%) subjects met the eligibility criteria during the baseline period. Of these, 38 (10.1%) were fFN positive, 10 (2.6%) had a spontaneous preterm delivery within 7 days of testing and 12 (3.2%) had a spontaneous preterm delivery within 14 days of testing.
The medical records of 410 patients who presented with threatened preterm labor during the comparative 
Figure 2
Flowcharts showing inclusion of patients who presented with threatened preterm labor during period in which fetal fibronectin test was used as standard-of-care biochemical test (baseline period) (a) and during period in which placental alpha microglobulin-1 test was adopted (comparative period) (b) for assessment of risk of preterm delivery.
period were reviewed, and 43 (10.5%) were excluded from the analysis (Figure 2 ). Of these, 29 had a multiple gestation, eight had cervical dilatation ≥ 3 cm, two had membrane rupture confirmed at presentation, two had cervical cerclage, one did not have a digital examination performed and one had placenta previa at the time of presentation, which ultimately led to a medically indicated preterm delivery within 14 days of testing. Thus, 367/410 (89.5%) subjects met the eligibility criteria during the comparative period, of whom 17 (4.6%) were PAMG-1 positive, 12 (3.3%) had a spontaneous preterm delivery within 7 days of testing and 17 (4.6%) had a spontaneous preterm delivery within 14 days of testing. The mean maternal age of the eligible patients was 32.6 years for those presenting in the baseline period and 32.5 years for those in the comparative period. Mean gestational age at testing was 30.4 weeks for the patients who presented during the baseline period and 30.5 weeks for those in the comparative period. Obstetric and demographic characteristics of the patient populations seen during both periods are shown in Table 1 .
During the baseline period, the fFN test had a sensitivity, specificity, PPV and NPV of 30.0%, 90.5%, 7.9% and 97.9%, respectively, with a LR+ of 3.2 and a LR-of 0.8 for the prediction of spontaneous preterm delivery within 7 days of testing, and a sensitivity, specificity, PPV and NPV of 25.0%, 90.4%, 7.9% and 97.4%, respectively, with a LR+ of 2.6 and a LR-of 0.8 for the prediction of spontaneous preterm delivery within 14 days (Table 2) .
During the comparative period, the PAMG-1 test had a sensitivity, specificity, PPV and NPV of 50.0%, 96.9%, 35.3% and 98.3%, respectively, with a LR+ of 16.1 and Table 1 Characteristics of patients who presented with threatened preterm labor during period in which fetal fibronectin test was used as standard-of-care biochemical test (baseline period) and period in which placental alpha microglobulin-1 test was adopted (comparative period) for assessment of risk of spontaneous preterm delivery Data are given as mean ± SD or n (%). GA, gestational age.
a LR-of 0.5 for the prediction of spontaneous preterm delivery within 7 days, and a sensitivity, specificity, PPV and NPV of 41.2%, 97.1%, 41.2% and 97.1%, respectively, with a LR+ of 14.4 and a LR-of 0.6 for the prediction of spontaneous preterm delivery within 14 days ( Table 2 ). The analysis comparing the performance of each biochemical test during their respective time periods showed no statistical difference in sensitivity for the prediction of spontaneous preterm delivery within 7 or 14 days of testing (P = 0.4149 and P = 0.4495, respectively). Additionally, there was no statistical difference in NPV for the prediction of spontaneous preterm delivery within 7 or 14 days of testing (P = 0.7858 and P = 1.0000, respectively). However, a statistical difference was observed between PAMG-1 and fFN with respect to Data are presented as n/N (% (95% CI)) or LR (95% CI). P calculated using Fisher's exact test. *Statistically significant (P < 0.05). LR-, negative likelihood ratio; LR+, positive likelihood ratio; NPV, negative predictive value; PPV, positive predictive value. each test's specificity (P = 0.0004 and P = 0.0002) and PPV (P = 0.0187 and P = 0.0062) for the prediction of spontaneous preterm delivery within 7 and 14 days, respectively ( Table 2) .
DISCUSSION
In this study, the accuracy of the fFN and PAMG-1 tests for the prediction of spontaneous preterm delivery within 7 and 14 days of testing was compared in symptomatic women in an acute hospital setting, using real-life data by retrospectively reviewing the medical records of subjects who had presented to Cruces University Hospital for evaluation of preterm labor.
Prior to switching to PAMG-1, fFN was the standard biochemical test for the risk assessment of spontaneous preterm delivery at our institution for several years. Our retrospective audit of each test's real-life performance over separate 1-year periods showed that we were more than twice as likely to get a positive biochemical test result when using fFN than with PAMG-1, while the rate of discharging women who ultimately delivered spontaneously within 14 days of testing was not affected. Furthermore, a positive PAMG-1 test was more than four times as reliable as a positive fFN test in predicting imminent spontaneous preterm delivery.
As it is well known that diagnostic predictive values are affected by the prevalence of the disease 10 , it was to be expected that our study would show, for both PAMG-1 and fFN, PPVs for the prediction of imminent spontaneous preterm delivery that were lower than those of earlier reports comparing the two tests, which did not use the same diagnostic approach (Figure 1 ) to evaluate patients with threatened preterm labor. Whereas Nikolova et al. 11 reported a rate of spontaneous preterm delivery within 7 days of 17.2% and PPVs for the prediction of spontaneous preterm delivery within 7 days of 76% and 29% for PAMG-1 and fFN, respectively, we found rates of spontaneous preterm delivery within 7 days of 2.6% for the baseline and 3.3% for the comparative period and PPVs for the prediction of spontaneous preterm delivery within 7 days of 35% and 8% for PAMG-1 and fFN, respectively. In both instances, the relative difference in PPV was roughly three times higher in favor of PAMG-1. While several other studies have compared the PAMG-1 test with the fFN test 11, 12 , ours is the first to compare the screening performance of the two tests using real-life data in a low-prevalence cohort representative of clinical settings (e.g. the USA) in which universal CL measurement by transvaginal ultrasound is not a mainstay of routine practice.
A major strength of our study arises from the fact that our performance evaluation of the PAMG-1 and fFN tests was based on real-life data collected over the course of two separate 12-month periods during which these tests served as part of standard clinical practice. As a result, the performance reported probably reflects what can be expected in routine clinical practice when using a diagnostic algorithm such as that shown in Figure 1 . Another strength of our study is the high number of patients, which should make our results generally applicable. A limitation of our study is its retrospective design. Furthermore, CL measurements were not included, since transvaginal ultrasound was fully implemented only after the baseline period of our study. To ensure comparability between the two time periods, CL measurements from the comparative period were excluded from our analysis. As the PAMG-1 test was always done prior to CL measurement, and thus on the same population type as was the fFN test during the baseline period, there is no reason to suppose that the use of CL measurements on transvaginal ultrasound had any effect on the performance reported for the PAMG-1 test.
We believe that our results have important implications for daily practice. In addition to providing a similar NPV, the superior PPV of the PAMG-1 test to that of the fFN test may lead to better classification of women at greater risk of imminent spontaneous preterm delivery who truly require inpatient observation and antenatal corticosteroids, resulting in a potential reduction in the number of unnecessary admissions and interventions. In addition to performance advantages, a PAMG-1 test sample can be obtained without a speculum examination, which may prove useful in rural areas. Furthermore, the PAMG-1 test can be done shortly after a vaginal examination, which may be useful for those patients transferred from lower-risk facilities, who had already had a vaginal exam or transvaginal ultrasound assessment 13 .
